T Cell: 10305 Clinical Trials, Page 15 of 1031

Hide Studies Not Open or Pending


Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Condition(s):CD19 Positive; CD22 Positive; Minimal Residual Disease; Progressive Disease; Recurrent B Acute Lymphoblastic Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Non-Hodgkin Lymphoma; Refractory B Acute Lymphoblastic Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Non-Hodgkin LymphomaLast Updated:June 19, 2020Not yet recruiting

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.